LungAlert™ Smokers Study
This 500-patient trial is designed to determine LungAlert™'s effectiveness in detecting early-stage cancers, particularly in smokers, and to establish the relationship between LungAlert™ values and the stage and size of tumors. The study is also looking at the effect of treatment on LungAlert™ values at one, three, six, nine and 12-month intervals post-surgery.
Participants include 100 lung cancer patients, 200 healthy smokers and 200 individuals with benign lung disease.
Interim findings of this study, which examined 122 subjects, showed LungAlert™’s reactivity in sputum samples may be useful as an initial screening test to identify high-risk subjects who would benefit from other tests, such as spiral computed tomography. Patients with cancer had significantly higher values than those who did not. The majority of these patients had early-stage disease where surgery for cure is a possibility.
View Abstract - Clinical Evaluation of a New Screening Test for Lung Cancer Based on
GOS Reactivity in Sputum Samples
View Abstract - Examination of Association of GOS Reactivity in Sputum with Lung Cancer |
